Federal contract award
75A50122F33003
ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75A50120D00015 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $3.8M |
| Current contract value | $3.8M |
| Potential contract value / ceiling | $3.9M |
| Start date | Sep 19, 2022 |
| Current end date | Sep 18, 2027 |
| Potential end date | Sep 18, 2027 |
| Latest award activity | Jul 21, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 12 of 12 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 21, 2026 | P00011 | $0 | STATISTICAL AND DATA COORDINATING SERVICES FOR THE ANTHRAX BOOST EVALUATION AND ANTIGEN-SPARING TRIAL |
| Jun 15, 2026 | P00010 | $0 | EO 14398. STATISTICAL AND DATA COORDINATING SERVICES FOR THE ANTHRAX BOOST EVALUATION AND ANTIGEN-SPARING TRIAL |
| Mar 30, 2026 | P00009 | $0 | STATISTICAL AND DATA COORDINATING SERVICES FOR THE ANTHRAX BOOST EVALUATION AND ANTIGEN-SPARING TRIAL |
| Aug 11, 2025 | P00008 | $153.6K | STATISTICAL AND DATA COORDINATING SERVICES FOR THE ANTHRAX BOOST EVALUATION AND ANTIGEN-SPARING TRIAL |
| Apr 22, 2025 | P00007 | $0 | STATISTICAL AND DATA COORDINATING SERVICES FOR THE ANTHRAX BOOST EVALUATION AND ANTIGEN-SPARING TRIAL |
| Aug 14, 2024 | P00006 | $0 | SDCC: ABEAST STUDY |
| May 6, 2024 | P00005 | $0 | SDCC: ABEAST STUDY |
| Jan 25, 2023 | P00004 | $0 | SDCC: ABEAST STUDY |
| Nov 9, 2022 | P00003 | $0 | SDCC: ABEAST STUDY |
| Oct 13, 2022 | P00001 | $0 | ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST) |
| Oct 13, 2022 | P00002 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO REVISE ARTICLE E. DELIVERABLES/SCHEDULE - KICKOFF MEETING DUE DATE FROM: WITHIN 30 CALENDAR DAYS OF THE AWARD TO: WITHIN 45 CALENDAR DAYS OF AWARD |
| Sep 19, 2022 | 0 | $3.7M | ANTHRAX AV7909 BOOST EVALUATION AND ANTIGEN-SPARING TRIAL (ABEAST) |
Estimated positioning window
Nov 1, 2026 – Mar 18, 2027
75/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 75/100. Available recorded signals: 70 points.
- Contract end 2027-09-18 (321 days from calculation)
- +35 points
- 15 historical awards in this buyer and category group
- +15 points
- 12 recorded award transactions
- +10 points
- Latest award action: 2026-07-21
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.